The global shift towards preventive medicine and personalized healthcare is driving demand for less invasive, more accessible diagnostic tools. With rising cancer incidence worldwide, there's an urgent need for technologies that can facilitate early detection without the discomfort or risks associated with traditional biopsies or extensive imaging. This technology aligns perfectly with these trends, offering a scalable solution for widespread screening and disease monitoring, reducing the economic and human toll of late-stage diagnoses.
Significantly Reduces Patient Burden and Invasiveness: Utilizes body fluid samples like saliva, eliminating invasive procedures such as blood draws or endoscopy. This minimizes patient physical and psychological stress, potentially increasing screening participation rates.
Enhances Early Diagnosis Accuracy: Identifies cancer-specific VOC profiles across three categories: 'disappearing group,' 'newly appearing group,' and 'fluctuating group.' This multi-faceted approach could offer higher diagnostic accuracy than conventional single-marker methods.
Provides Simple Operation and Rapid Results: Combines body fluid samples, which require minimal pre-processing, with established VOC detection technologies. This simplifies the testing process, enabling quick diagnostic results.
This patent protects a method and system for assisting cancer diagnosis by detecting specific volatile organic compound (VOC) profiles in body fluids. The claims broadly cover the identification of VOC groups indicative of cancer and the use of determination criteria for diagnosis. The patent was granted after successfully addressing examiner rejections, indicating a robust and stable scope of protection against prior art.
Adjacent white space exists in applying VOC analysis to non-cancerous conditions like infectious or metabolic diseases, or in developing novel, non-GC/MS-based VOC collection and pre-processing technologies that could enhance the system's utility without infringing on the core diagnostic logic.
If an adopting company deploys a screening service using this technology, significant treatment cost reductions from early cancer detection are anticipated. For example, replacing conventional detailed examination costs of ~$650/person (AI est.) for 1,500 patients annually could result in an estimated $1M/year (AI est.) in healthcare cost savings ($650/person × 1,500 patients = $975K, rounded to $1M). This estimate also considers indirect economic benefits such as reduced treatment costs for advanced cancer and improved patient quality of life.
X: Early Diagnosis Accuracy & Speed
Y: Non-Invasiveness & Patient Burden Reduction